Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POMMAC
2024-515958-24-00Phase 3Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute cholecystitis comparing Invanz arm with Cefuroxime + ciprofloxacin arm (2 arms). Primary endpoint: Postoperative infectious complications within 30 days from randomisation. Planned start Apr 2025; status: authorised.
02
Drugs
ertapenemciprofloxacincefuroxime
03
Conditions
acute cholecystitis
Beyond the preview
Go deeper on 2024-515958-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515958-24-00.